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Abstract
This article gives an overview of some of the ongoing challenges that are faced in the prevention,
diagnosis and treatment of malaria.
Malaria causes approximately 881,000 deaths every year, with nine out of ten deaths occurring in
sub-Saharan Africa. In addition to the human burden of malaria, the economic burden is vast. It is
thought to cost African countries more than US$12 billion every year in direct losses.
However, great progress in malaria control has been made in some highly endemic countries. Vector
control is assuming a new importance with the significant reductions in malaria burden achieved
using combined malaria control interventions in countries such as Zanzibar, Zambia and Rwanda.
The proportion of patients treated for malaria who have a confirmed diagnosis is low in Africa
compared with other regions of the world,with the result that anti-malarials could be used to treat
patients without malaria,especially in areas where progress has been made in reducing the malaria
burden and malaria epidemiology is changing. Inappropriate administration of anti-malarials could
contribute to the spread of resistance and incurs unnecessary costs.
Parasite resistance to almost all commonly used anti-malarials has been observed in the most lethal
parasite species, Plasmodium falciparum.This has presented a major barrier to successful disease
management in malaria-endemic areas.
ACT (artemisinin-based combination therapy) has made a significant contribution to malaria
control and to reducing disease transmission through reducing gametocyte carriage. Administering
ACT to infants and small children can be difficult and time consuming. Specially formulating anti-
malarials for this vulnerable population is vital to ease administration and help ensure that an
accurate dose is received.
Education of healthworkers and communities about malaria prevention,diagnosis and treatment is
a vital component of effective case management, especially as diagnostic policies change.
Preventing resistance emerging to both ACT and insecticides used in vector control remains an on-
going challenge in an era of changing malaria epidemiology.
Open AccessBackground
Malaria is one of the world’s most deadly diseases. Even
though it is highly preventable and treatable, it causes
approximately 881,000 deaths every year [1], with nine
out of ten deaths occurring in sub-Saharan Africa, and
85% of malaria-related deaths in children under five years
of age. This is the equivalent of a child dying of malaria in
Africa every 30 seconds [2]. The most serious forms of the
disease are caused by the parasite Plasmodium falciparum;
malaria caused by Plasmodium vivax, Plasmodium ovale and
Plasmodium malariae results in milder disease in humans
that is not generally fatal. In 2008, 109 countries were
reported to be endemic for malaria, with 45 of the
countries within the African region [1]. There were an
estimated 247 million episodes of malaria in 2006, with
86% of cases reported in African countries [3].
The burden of malaria
Effective control and treatment of malaria presents
enormous logistical challenges. The key to addressing the
challenge of reducing the burden of malaria is an inte-
grated approach that combines preventative measures,
such as long-lasting insecticide-treated bed nets (LLINs)
and indoor residual spraying (IRS), with improved access
to effective anti-malarial drugs. However, malaria is a
disease that stems from and causes poverty, and many at-
risk populations live in extremely destitute, remote areas.
Poor, rural families are the least likely to have access to
these preventative measures that are fundamental to
malaria control, and may live kilometres from the nearest
healthcare facility. They are also less able to afford
treatment once infection has occurred [4].
In addition to the human cost of malaria, the economic
burden of the disease is vast. It is estimated that malaria
costs African countries more than US$12 billion every
year in direct losses [3], even though the disease could be
controlled for a fraction of that sum. For Nigeria alone the
direct loss to the economy is estimated at GBP530 million
annually [3]. Up to 40% of African health budgets are
spent on malaria each year [5], and on average, a malaria-
stricken family loses a quarter of its income through loss
of earnings and the cost of treating and preventing the
disease [2]. Malaria causes an average loss of 1.3% of
economic growth per year in Africa [3].
The growing prominence of vector control
The success of malaria control measures in some highly-
endemic countries, such as Rwanda, Zambia, Zanzibar,
Sao Tome & Principe, The Gambia and Kenya has led to
reductions in deaths from malaria of 50% or more [1]. In
these countries, the widespread use of LLINs and IRS,
together with treatment of uncomplicated Plasmodium
falciparum  malaria with artemisinin-based combination
therapy (ACT), have all contributed to the reported
reductions in malaria. Another article in this supplement
describes the impact of combined malaria control
interventions on disease burden [6].
These developments have led to an increased focus on
vector control. The historic successful eradication of
malaria in various parts of the world was achieved
primarily by vector control, indicating that renewed
efforts in this field, other than the current insecticide-
based strategies, should be considered a central aspect of
any malaria eradication strategy.
In the Roll Back Malaria (RBM) programme of the World
Health Organization (WHO), vector control is based
mainly on the continuation and upscaling of insecticide-
based strategies. However, given the increasing prevalence
of mosquito resistance against the currently used
chemicals, the need for development of new insecticides
has high priority. A multitude of novel malaria vector-
control tools has been developed in recent years, and
several of these are at an advanced stage, nearing broad-
scale implementation. Recently, successes were reported
in Kenya with Bacillus thuringiensis israelensis (Bti) for
larval control [7]. Novel tools for the control of the adult
mosquito include entomopathogenic fungi, insect-
pathogenic viruses, the introduction of genetically
engineered mosquitoes and the sterile insect technique
(SIT) [8]. Field-based trials in which the impact of these
vector-control tools on public health is properly
measured are needed before they can be adopted to
complement the malaria control tools currently in use.
Improving malaria diagnosis
Accurate diagnosis is a vital part of good malaria case
management and is becoming increasingly important as
the need for presumptive treatment of fever declines
along with malaria burden in many areas. The proportion
of people treated for malaria who have a confirmed
diagnosis is low in the African Region compared with
other regions of the world [1], with the result that anti-
malarials could be used to treat patients without malaria.
Biological diagnostic methods such as rapid diagnostic
tests (RDTs) are easy to use, give fast results and are
increasingly affordable. As RDTs become more widely
available, confirmation of malaria prior to treatment will
become the standard procedure. The introduction of
RDTs at the community level needs to be carefully
planned, to include transport and storage considerations,
local sensitivity testing and establishment of a compre-
hensive quality assessment/control system. Overcoming
the tendency of some prescribers to treat with ACT despite
a negative test result poses a significant challenge; training
of end users should include how to manage positive and
negative test results, and should also emphasize that a
negative result is valid. There are currently no inter-
Malaria Journal 2009, 8(Suppl 1):S2 http://www.malariajournal.com/content/8/S1/S2
Page 2 of 6
(page number not for citation purposes)national guidelines or treatment algorithms for the
management of negative tests results. Adequate training,
supervision and follow-up are essential to achieving a
change in perceptions and practice.
New WHO guidelines, due for publication in 2009, are
expected to recommend that anti-malarials should not be
given to febrile patients unless the parasitological
presence of malaria has been confirmed by laboratory or
rapid diagnostic testing. This reduces the unnecessary
administration of these drugs and may also help to
combat the spread of resistance by ensuring that only
malaria patients receive this treatment. It will also mean
that patients who present with a fever but do not have
malaria are more likely to be given an appropriate
treatment more rapidly.
This revised approach to malaria diagnosis may also have
an impact on patients’ perceptions of anti-malarial
therapies. Patients will have greater confidence in a
therapy if it is shown to work quickly and effectively. If an
ACT is administered for a non-malarial infection, the
patient will not feel satisfied as the drug will not improve
their symptoms. The patient may, therefore, be less likely
to adhere to an ACT regimen in the future if an actual
diagnosis of malaria is made, due to their previously
negative experience with that drug. Thus, it is vital that the
initial diagnosis is correct to encourage future compliance.
Drug resistance as a barrier to malaria control
The development and spread of parasite resistance to
certain anti-malarial agents has presented a major barrier
to successful disease management in malaria-endemic
areas, and has probably contributed to the resurgence of
infection and the increase in malaria-related deaths in
recent years [9]. Resistance to almost all commonly used
anti-malarials, notably chloroquine and sulphadoxine-
pyrimethamine, but also amodiaquine, mefloquine, and
quinine, has been observed in the most lethal parasite
species, P. falciparum [9]. The problem of resistance exists
in much of Africa and Southeast Asia [10–12]; for
example, treatment failure rates of around 70–80% have
been reported for chloroquine [10], which was formerly
the cheapest and most widely available anti-malarial
drug. There is also increasing drug resistance to amodia-
quine in large parts of East Africa, potentially rendering
the combination of artesunate and amodiaquine less
effective [11].
Artemisinin derivatives are the only class of anti-malarial
agents to which P. falciparum resistance has not been
reported in Africa [9], and as a result the WHO called for
the use of artemisinin in combination therapies in
September 2005 [4,5]. In January 2006, WHO called for
termination of the distribution and sale of artemisinin
monotherapies by pharmaceutical companies [9].
Unfortunately, many companies are yet to comply,
creating a further barrier to disease control. In addition,
substandard drugs and counterfeits pose a major
problem. Anti-malarial drugs are widely available outside
the public health services; for example, from pharmacies,
shops, private practitioners and other outlets. It is thought
that up to 35% of all anti-malarial treatments sold in
Africa are sub-standard [13].
The half-life of anti-malarials is believed to be an impor-
tant factor in the development and spread of resistance
[14,15]. It has been suggested that compounds with a
longer half-life have a greater propensity to become
ineffective due to parasite resistance. For a drug that has a
half-life of weeks or months (e.g. mefloquine, pipera-
quine or chloroquine), the slow elimination from the
host’s blood enables parasites to be exposed to residual
drug concentrations. Malaria parasites will not be exposed
to partially effective drug concentrations if the drugs are
eliminated during the two-day life cycle of the asexual
parasite [14]. However, it has also been proposed that a
longer half-life offers protection against re-infection for a
longer period of time – this effect is known as “post-
treatment prophylaxis”, and represents the period of time
after an anti-malarial treatment dose during which re-
infection is suppressed [16,17]. Thus, what benefits the
individual patient may be detrimental to society if there is
a greater risk of resistance developing as more parasites
are exposed to sub-therapeutic drug levels.
Using anti-malarials that have evolved from similar basic
chemical compounds can lead to an increase in the
development of resistance. For example, the relatively
high rate of treatment failure reported with the ACT
dihydroartemisinin–piperaquine against P. falciparum
may be attributed to cross-resistance between chloroquine
and piperaquine [18]. This may reduce the usefulness of
new therapies prior to large-scale deployment if they are
derivatives of currently used drugs to which resistance has
already been established.
Reducing malaria transmission
Using effective anti-malarials
Rapid treatment of malaria cases with a treatment that
quickly reduces the parasite load and is also strongly
gametocidal can help reduce the rate of malaria
transmission.
Artemisinin derivatives are extremely potent anti-
malarials with a rapid onset of action, and when adminis-
tered in combination with anti-malarial drugs with slower
elimination rates (e.g. lumefantrine), short courses of
treatment (three days) have proved to be highly effective
[9]. The less effective single-drug treatments increase the
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treatment; combining anti-malarial drugs with indepen-
dent modes of action can impede the development of
resistance to each individual component of the
combination. In the rare event that a mutant parasite
resistant to one of the drugs arises de novo during the
course of an infection, the parasite will be killed by the
other drug in the combination [9].
Artemisinin derivatives can reduce parasite load by a
factor of approximately 10,000 per asexual cycle [19],
compared with a reduction of 100-fold to 1,000-fold per
cycle with most other anti-malarial drugs [9]. They also
have gametocidal properties, which could have an impor-
tant effect on the incidence of malaria. Artemether can
lower transmission of the infection by inhibiting gameto-
cyte development, thus reducing the dissemination of
resistant parasites. Evidence has shown a more rapid time
to gametocyte clearance with artemether/lumefantrine
(AL) than with other anti-malarial combinations [20].
A study in the Tigray region of Ethiopia compared
community deployment of AL with traditional health
facility-based care, finding that even during a major
malaria epidemic, malaria transmission was decreased.
The control district (health facility based-care) had a
three-fold higher crude parasite rate (all species and
stages), a two-fold higher crude asexual parasite rate
(P. vivax and P. falciparum) and an approximately three-
fold higher P. falciparum rate (both asexual and
gametocyte stages) than the intervention (community
deployment) district (Figure 1). This indicates that the
intervention had an effect, as all other vector control
activities were comparable, with even better coverage in
the control district [21].
Treatment of asymptomatic carriers
Asymptomatic carriers of P. falciparum are likely to be
essential for maintaining the cycle of infection in areas of
high malaria transmission. Treatment of asymptomatic
carriers could help reduce disease transmission by
depleting the reservoir of parasites available for infection
of mosquitoes. In comparison with non-artemisinin
regimens, treatment with artemisinin derivatives has been
shown to result in lower gametocyte carriage rates [22,23],
and reduced infectivity of treated individuals [24].
In a study in The Gambia, children treated with AL were
significantly less likely to carry gametocytes within the
four weeks following treatment than those receiving
chloroquine and sulphadoxine-pyrimethamine (p<0.0001)
[24]. In addition, children who received AL harboured
gametocytes for shorter periods following treatment
(p<0.0001) and were less infective to mosquitoes at day 7
(p<0.001) [24].
However, before the treatment of asymptomatic carriers
can be considered as a new tool in the efforts to eliminate
malaria, evidence of the proof of concept will need to be
generated from suitably powered trials.
Role of bed nets
Widespread deployment of LLINs has proved a very
successful contribution to malaria control strategy. In
Rwanda, Ethiopia, and Zanzibar, the mass distribution of
insecticide-treated bed nets and nationwide adoption of
ACT resulted in substantial declines in malaria-related
deaths [25,26]. However, the impact of LLINs distribution
can be lost if vulnerable populations do not use the nets
or re-purpose them. A study in western Kenya found that
30% of bed net recipients did not adhere to net use
[27,28]. A study of fishing villages on Lake Victoria in
Kenya reported bed nets being used for fishing and drying
fish, with reasons given that the nets were inexpensive or
free and allowed the fish to dry very quickly [29].
In addition, the effectiveness of bed nets in helping to
prevent disease transmission is dependent on their
integrity and longevity. A study in Ghana revealed that
only 14.9% of 255 nets collected for analysis 38 months
after distribution had retained their full insecticidal
strength. Of 50 nets examined for holes, more than 40%
contained holes of more than 0.5 cm diameter, and 50%
had seam failures [30].
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Figure 1
Malaria parasite reservoir in the control and intervention
districts of the Tigray study region. Malaria parasite reservoir
was 3-fold lower in the intervention district during 2005
high-transmission season.Meeting the need for a paediatric formulation
The provision of an appropriate formulation of ACT for
infants and young children, who bear the greatest burden
of malaria, presents a particular challenge. Administering
anti-malarials to infants and small children can be
difficult, stressful, and time consuming. Many malaria
tablets need to be crushed and mixed with food or water
to ease administration to young children, and the bitter
taste can cause children to spit out the crushed tablets
and, therefore, possibly not receive an optimal dose that
will cure the malaria infection. Some existing paediatric
drugs are presented as syrups or suspensions, which can
be bulky to supply and store, and the stability and
hygiene of the formulation cannot be guaranteed after
opening. Accurate dosing of syrups may be difficult as it
requires precise volume measurement in the field.
A new dispersible formulation of AL, specifically designed
for children, has proved in clinical trials to be as safe and
effective as the regular tablet formulation [31]. Disper-
sible AL tablets (Coartem® Dispersible) rapidly disperse in
a small amount of water to produce a sweet-tasting
formulation for ease of administration to infants and
children [32]. Accurate dosing is aided by Coartem®
Dispersible tablets (as with regular Coartem® tablets)
being administered as a fixed dose, according to specific
weight categories of the patients [32,33].
Training, educating and sharing best practice
Educating healthcare workers and patients about the
prevention and treatment of malaria is another challenge
in the management of the disease. Novartis has an
ongoing commitment to developing initiatives, such as
educational materials and training courses for healthcare
workers, and the communities they serve; examples
include a malaria case management programme for
nurses in Zambia, and the development of educational
materials for healthcare workers and mothers/caregivers,
which have been translated into several African languages
and are distributed free of charge to countries on request.
One of the greatest difficulties in reducing the toll of
malaria is reaching remote communities with poor
transport systems, and achieving timely reordering to
maintain supplies of ACT. The procurement of anti-
malarial medicines through public health services
increased sharply between 2001 and 2006, but access to
treatment, especially ACT, was inadequate in all countries
surveyed in 2006 [1]. Novartis is helping to address these
challenges by hosting a series of biannual workshops in
Africa, at which national malaria control programme
(NMCP) managers can share information regarding best
practice in their countries, including topics such as
community awareness, healthcare worker training, stock
management and distribution, and health impact
measurement. Participants can also share expertise on
how to forecast demand for AL, as well as discussing
ordering and distribution systems, and routes for
financing and procurement.
Conclusion
Malaria continues to be a significant public health issue
and a major hindrance to economic growth. Sustained
control and management of malaria presents significant
challenges. Effective interventions are available; these
include widespread implementation of effective vector
control measures such as LLINs and IRS, and prompt and
effective treatment with ACT following accurate diagnosis.
Reducing malaria transmission by reducing gametocyte
carriage with effective drugs can be an important factor in
highly endemic areas. Some endemic countries are
forging a path in malaria control and prevention using
combined interventions and have achieved significant
reductions in malaria burden.
However, factors such as patient access to effective
treatments and preventative measures, availability of
training programmes and educational materials, and
development and spread of resistance to certain anti-
malarials are hindering progress.
Addressing the continuing challenges presented by
malaria in the years ahead will require responsive
strategies such as innovative vector control methods,
widespread implementation of biological diagnosis prior
to treatment with effective anti-malarials, and close
monitoring of local malaria epidemiology to identify
areas of resurgence. Tight control of the regulatory
environment to ensure provision of high-quality drugs
and appropriate dosing advice will be vital to promoting
compliance and preserving effectiveness of ACT.
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